Located in Cambridge,
our laboratory works at
the interface of chemistry
and biology with a focus
on protein chemistry and
targeted cancer therapeutics.
LATEST NEWS
Our work on discovering Piperlongumine as a SARS-CoV-2 host-directed antiviral has been published in ACS Central Science and highlighted in EurekAlert and MedicalExpress, here. This study reveals that Piperlongumine selectively induces an increase in ROS levels in infected cells and significantly inhibits disease progression in a mouse model. It provides a new approach to combat SARS-CoV-2 variants and even other viruses. Check out the EurekAlert and Medical Express articles and our research paper.
LATEST NEWS
Our new method that ‘masks’ cancer-killing drugs and avoids harming healthy cells has now been published! This new approach uses a molecular carrier to deliver ortho-quinones directly to specific cells and shield healthy cells from the drug. You can read a News & Views about our work, here, and news article about our work here. If you want to learn more, you can read the full article in Nature Chemistry, here.